- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Are Orphan Diseases an Entry Point to Larger Markets?
Summary
23 Jul 2008-30 Jul 2008 — Webinar
This presentation is based on our Orphan Disease Series reports. Orphan drug status can offer companies a number of unique advantages for their agents, particularly as competition increases in larger disease states and the hurdles to gaining regulatory approval increase.
Contact details
Alison Fautré email: afautre@decisionresources.be phone: +32 2 357 06 15
Venue
Webinar
Webinar — 23 Jul Wed + 30 Jul Wed
To be held on two different dates - 23 July and 30 July 2008
You are invited to attend a complimentary webinar from Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues.
This presentation is based on our Orphan Disease Series reports. Orphan drug status can offer companies a number of unique advantages for their agents, particularly as competition increases in larger disease states and the hurdles to gaining regulatory approval increase. The Orphan Disease Series provides critical market information for diseases with smaller patient populations, including disease prevalence, profiles of marketed and emerging agents and insight into the prescribing choices of disease specialists. These reports will help you to maximize the potential of your agents in these challenging markets, including insights into the regulatory benefits available and the potential for partnership with charitable organizations.
Select titles from the Orphan Disease Series include:
* Amyotrophic Lateral Sclerosis: Strategies for Drug Developers
* Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?
* Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market?
Presented by Decision Resources' Program Manager Jennifer Moniz Carpenter, M.B.A. the webinar will answer the following questions:
* How did makers of drugs like Remicade, Gleevec and Rituxan incorporate orphan drug designation in their lifecycle strategies?
* How has the Orphan Drug Act changed drug development? How many diseases are currently designated as orphan and how many drugs have received orphan status?
* What incentives do regulatory agencies offer to developers of orphan drugs? How do orphan drug policies differ across geographic regions? What other incentives are available for developers of orphan drugs?
* What opportunities do glaucoma, amyotrophic lateral sclerosis and cystic fibrosis offer to agents looking for an entry point into larger markets? Which drugs in these markets could jump to larger patient populations?
Jennifer Moniz Carpenter and New Product Development Vice President Jason LaBonte, Ph.D., will conduct a live question and answer session after the presentation.
REGISTRATION
July 23, 2008 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris)
To register, click here to reach our WebEx Event Center page, then click "Register" for this event.
July 30, 2008 at 2 p.m. U.S. Eastern Time, 11 a.m. U.S. Pacific Time
To register, click here to reach our WebEx Event Center page, then click "Register" for this event.
*This webinar will be held on both dates, there is no fee to attend the webinar and it is open to anyone who would like to attend. If you have any questions or issues regarding registration, please contact Alison Fautré at afautre@decisionresources.be
For pricing information on the Orphan Disease Series reports, please contact:
In North America - Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com
In Europe - Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be
In Japan - Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us